Form 4: Revolution Medicines Executive Sells Shares Under 10b5-1 Trading Plan

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold shares of common stock on September 13, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On September 13, 2024, Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, executed transactions involving the company's common stock.
• These transactions included the exercise of stock options and the sale of common stock.
• The sales were conducted under a 10b5-1 trading plan adopted on March 15, 2024.
• A total of 16,667 shares were acquired through the exercise of stock options at a price of $4.09 per share.
• Simultaneously, 5,966 shares were sold at a weighted average price of $42.7493, and 10,701 shares were sold at a weighted average price of $43.645.
• Following these transactions, Kelsey directly owns 269,073 shares of common stock, which includes 95,476 restricted stock units, and 39,998 stock options.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions were executed under a pre-arranged 10b5-1 trading plan. It's a routine filing and doesn't necessarily indicate positive or negative sentiment about the company's future.

Industry Context

Insider trading activity is closely monitored by investors as it can provide insights into management's perspective on the company's prospects. Sales under a 10b5-1 plan are generally viewed as less informative since they are pre-arranged.

Stakeholder Impact

• The sale of shares by a company executive may cause some short-term concern among shareholders, but the existence of a 10b5-1 trading plan mitigates this concern.

Key Dates